Endocrine Oncology

Jump to Content Jump to Main Navigation

Endocrine Oncology current issue cover

Current Issue

Endocrine Oncology 'now open for submissions' promotional advert

Submit your manuscript Author guidelines Journal scope Open access Publication charges Editorial Board

Endocrine Oncology key journal metrics

Average time to first response: 43 days

Acceptance rate: 29%

Browse the full Editorial Board

Hyponatraemia and the syndrome of inappropriate antidiuresis (SIAD) in cancer

Authors: D Mc Donald, M Sherlock, and C J Thompson

Potential pitfalls in diagnosis of immunotherapy-induced hypothalamic-pituitary-adrenal axis suppression

Authors: Darran Mc Donald and Rachel Katherine Crowley

Adjuvant therapy in adrenocortical carcinoma: prognostic factors and treatment options

Authors: Ruaa Al-Ward, Celeste Zsembery, and Mouhammed Amir Habra

Pheochromocytoma and paraganglioma: germline genetics and hereditary syndromes

Authors: Christie G Turin, Molly M Crenshaw, and Lauren Fishbein

Potential pitfalls in diagnosis of immunotherapy-induced hypothalamic–pituitary–adrenal axis abnormalities: a clinical case

Authors: Yixi Bi, Safwaan Adam, Viktoria Chatzimavridou, Paul Lorigan, and Yinglai Huang

January 26, 2021

Article Publication Charge Waived

In celebration of the launch of Endocrine Oncology, Bioscientifica is sponsoring the Article Publication Charge during the launch years of the journal.

January 26, 2021

Endocrine Oncology – now open for submissions

Bioscientifica is pleased to announce the launch of their new fully open-access, peer-reviewed journal, Endocrine Oncology, endorsed by the Society for Endocrinology.

Led by Editor-in-Chief Edward P Gelmann, Endocrine Oncology will see vigorous yet rapid peer review of the latest basic, translational and clinical research in the field.

Tweets by EndoOncology